Polycationic sulfonamides for the sequestration of endotoxin

Journal of Medicinal Chemistry

Volumn 50, Issue 4, 2007, Pages 877-888

  Burns, Mark R ^a   Jenkins, Scott A ^a   Kimbrell, Matthew R ^b   Balakrishna, Rajalakshmi ^b   Nguyen, Thuan B ^b   Abbo, Benjamin G ^b   David, Sunil A ^b  

^a MediQuest Therapeutics Inc   (United States)

^b UNIVERSITY OF KANSAS   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ENDOTOXIN; FATTY ACID; LIPOPOLYSACCHARIDE; POLYAMINE DERIVATIVE; SULFONAMIDE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CONTROLLED STUDY; CRITICAL ILLNESS; DRUG ACTIVITY; DRUG BIOAVAILABILITY; DRUG POTENCY; DRUG STRUCTURE; FEMALE; MORTALITY; MOUSE; NONHUMAN; SEPTIC SHOCK;

ANIMALS; CATIONS; CYTOKINES; FEMALE; HUMANS; LIPOPOLYSACCHARIDES; MICE; NF-KAPPA B; NITRIC OXIDE; SPERMINE; STRUCTURE-ACTIVITY RELATIONSHIP; SULFONAMIDES;

EID: 33847345468     PISSN: 00222623     EISSN: None     Source Type: Journal    
DOI: 10.1021/jm061198m     Document Type: Article

References (85)

1. Rietschel, E. T.; Kirikae, T.; Schade, F. U.; Mamat, U.; Schmidt, G.; Loppnow, H.; Ulmer, A. J.; Zähringer, U.; Seydel, U.; Di Padova, F.; et al. Bacterial endotoxin: Molecular relationships of structure to activity and function. FASEB J. 1994, 8, 217-225.
2. Hurley, J. C. Antibiotic-induced release of endotoxin. A therapeutic paradox. Drug Saf. 1995, 12, 183-195.
3. Gasche, Y.; Pittet, D.; Sutter, P. Outcome and prognostic factors in bacteremic sepsis. In Clinical trials for treatment of sepsis. Sibbald, W. J., Vincent, J. L., Eds.; Springer-Verlag: Berlin, 1995; pp 35-51.
4. Centers for Disease Control. Increases in national hospital discharge survey rates for septicemia - United States, 1979-1987. MMWR 1990, 39, 31-34.
5. Ulevitch, R. J. Molecular mechanisms of innate immunity. Immunol. Res. 2000, 21, 49-54.
6. Ulevitch, R. J.; Tobias, P. Recognition of Gram-negative bacteria and endotoxin by the innate immune system. Curr. Opin. Immunol. 1999, 11, 19-23.
7. Dinarello, C. A. Cytokines as mediators in the pathogenesis of septic shock. Curr. Top. Microbiol. Immunol. 1996, 216, 133-165.
8. Michie, H. R.; Manogue, K. R.; Spriggs, D. R.; Revhaug, A.; O'Dwyer, S.; Dinarello, C. A.; Cerami, A.; Wolff, S. M.; Wilmore, D. W. Detection of circulating tumor necrosis factor after endotoxin administration. N. Engl. J. Med. 1988, 318, 1481-1486.
9. Bone, R. C. The sepsis syndrome. Definition and general approach to management. Clin. Chest Med. 1996, 17, 175-181.
10. Galanos, C.; Lüderitz, O.; Rietschel, E. T.; Westphal, O.; Brade, H.; Brade, L.; Freudenberg, M. A.; Schade, U. F.; Imoto, M.; Yoshimura, S.; Kusumoto, S.; Shiba, T. Synthetic and natural Escherichia coli free lipid A express identical endotoxic activities. Eur. J. Biochem. 1985, 148, 1-5.
11. Imoto, M.; Yoshimura, H.; Kusumoto, S.; Shiba, T. Total synthesis of lipid A, active principle of bacterial endotoxin. Proc. Jpn. Acad. Sci. 1984, 60, 285-288.
12. Kotani, S.; Takada, H.; Tsujimoto, M.; Ogawa, T.; Takahashi, I.; Ikeda, T.; Otsuka, K.; Shimauchi, H.; Kasai, N.; Mashimo, J.; Nagao, S.; Tanaka, A.; Tanaka, S.; Harada, K.; Nagaki, K.; Kitamura, H.; Shiba, T.; Kusumoto, S.; Imoto, M.; Yoshimura, H. Synthetic lipid A with endotoxic and related biological activities comparable to those of a natural lipid A from an Escherichia coli Re-mutant. Infect. Immun. 1985, 49, 225-237.
13. Kusumoto, S.; Kamikawa, T.; Kurosawa, M.; Fukase, K.; Shiba, T.; Kusama, T.; Soga, T.; Shioya, E.; Nakayama, K.; Nakayima, H.; Osada, Y.; Ono, Y. New results in the synthesis of lipid A and endotoxins. In Endotoxin Research Series, Nowotny, A., Ed., Vol. 1. Cellular and molecular aspects of endotoxin reactions; Nowotny, A., Spitzer, J. J., Ziegler, E. J., Eds.; Elsevier Science Publishers: Amsterdam, 1990; pp 41-51.
14. Holst, O.; Ulmer, A. J.; Brade, H.; Rietschel, E. T. On the chemistry and biology of bacterial endotoxic lipopolysaccharides. In Immunotherapy of infections: Masihi, N., Ed.; Marcel Dekker, Inc.: New York, Basel, Hong Kong, 1994; pp 281-308.
15. Rietschel, E. T.; Wollenweber, H. W.; Sidorczyk, Z.; Zähringer, U.; Lüderitz, O. Analysis of the primary structure of lipid A. In Bacterial Lipopolysaccharides: Structure, Synthesis and Biological Activities. Anderson, L., Unger, F. M., Eds.; ACS Symposium Series; American Chemical Society: Washington, DC, 1983; pp 195-212.
16. Ferguson, A. D.; Hofmann, E.; Coulton, J.; Diedrichs, K.; Welte, W. Siderophore-mediated iron transport: Crystal structure of FhuA with bound lipopolysaccharide. Science 1998, 2215-2220.
17. Kirikae, T.; Schade, F. U.; Zähringer, U.; Kirikae, F.; Brade, H.; Kusumoto, S.; Kusama, T.; Rietschel, E. T. The significance of the hydrophilic backbone and the hydrophobic fatty acid regions of Lipid A on macrophage binding and cytokine induction. FEMS Immunol. Med. Microbiol. 1994, 8, 13-26.
18. Kusumoto, S.; Inage, M.; Chaki, H.; Imoto, M.; Shimamoto, T.; Shiba, T. Chemical synthesis of lipid A for the elucidation of structure-activity relationships. In Bacterial lipopolysaccharides: structure, synthesis, and biological activities; Anderson, L., Unger, F. M., Eds.; American Chemical Society: Washington, DC, 1983; pp 237-254.
19. Martin, G. S.; Mannino, D. M.; Eaton, S.; Moss, M. The epidemiology of sepsis in the United States from 1979 through 2000. N. Engl. J. Med. 2003, 348, 1546-1554.
20. Cross, A.; Opal, S. M. Therapeutic intervention in sepsis with antibody to endotoxin: Is there a future? J. Endotoxin Res. 1994, 1, 57-59.
21. Hosac, A. M. Drotrecogin alfa (activated): The first PDA-approved treatment for severe sepsis. Proc. (Baylor Univ. Med. Cent.) 2002, 15, 224-227.
22. Eichacker, P. Q.; Danner, R. L.; Suffredini, A. F.; Cui, X.; Natanson, C. Reassessing recombinant human activated protein C for sepsis: Time for a new randomized controlled trial. Crit. Care Med. 2005, 33, 2426-2428.
23. Castelli, E. E.; Culley, C. M.; Fink, M. P. Challenge and rechallenge: Drotrecogin alfa (activated)-induced prolongation of activated partial thromboplastin time in a patient with severe sepsis. Pharmacotherapy 2005, 25, 1147-1150.
24. Abraham, E.; Laterre, P. F.; Garg, R.; Levy, H.; Talwar, D.; Trzaskoma, B. L.; Francois, B.; Guy, J. S.; Bruckmann, M.; Rea-Neto, A.; Rossaint, R.; Perrotin, D.; Sablotzki, A.; Arkins, N.; Utterback, B. G.; Macias, W. L. Drotrecogin alfa (activated) for adults with severe sepsis and a low risk of death. N. Engl. J. Med. 2005, 353, 1332-1341.
25. Visintin, A.; Halmen, K. A.; Latz, E.; Monks, B. G.; Golenbock, D. T. Pharmacological inhibition of endotoxin responses is achieved by targeting the TLR4 coreceptor, MD-2. J. Immunol. 2005, 175, 6465-6472.
26. Hawkins, L. D.; Christ, W. J.; Rossignol, D. P. Inhibition of endotoxin response by synthetic TLR4 antagonists. Curr. Top. Med. Chem. 2004, 4, 1147-1171.
27. Ondiveeran, H. K.; Fox-Robichaud, A. Drug evaluation: E-5564. IDrugs 2004, 7, 582-590.
28. Rossignol, D. P.; Lynn, M. Antagonism of in vivo and ex vivo response to endotoxin by E5564, a synthetic lipid A analogue. J. Endotoxin Res. 2002, 8, 483-488.
29. Beutler, B.; Poltorak, A. The sole gateway to endotoxin response: How LPS was identified as TLR4, and its role in innate immunity. Drug Metab. Dispos. 2001, 29, 474-478.
30. Poltorak, A.; He, X.; Smirnova, I.; Liu, M. Y.; Huffel, C. V.; Du, X.; Birdwell, D.; Alejos, E.; Silva, M.; Galanos, C.; Freudenberg, M.; Ricciardi, C. P.; Layton, B.; Beutler, B. Defective LPS signaling in C3H/HeJ and C57BL/10ScCr mice: Mutations in Tlr4 gene. Science 1998, 282, 2085-2088.
31. Ii, M.; Matsunaga, N.; Hazeki, K.; Nakamura, K.; Takashima, K.; Seya, T.; Hazeki, O.; Kitazaki, T.; Iizawa, Y. A novel cyclohexene derivative, ethyl (6R)-6-[N-(2-chloro-4-fluorophenyl)sulfamoyl]cyclohex-1-ene-1- carboxylate (TAK-242), selectively inhibits toll-like receptor 4-mediated cytokine production through suppression of intracellular signaling. Mol. Pharmacol. 2006, 69, 1288-1295.
32. Yamada, M.; Ichikawa, T.; Ii, M.; Sunamoto, M.; Itoh, K.; Tamura, N.; Kitazaki, T. Discovery of novel and potent small-molecule inhibitors of NO and cytokine production as antisepsis agents: Synthesis and biological activity of alkyl 6-(N-substituted sulfamoyl)-cyclohex-1-ene-1-carboxylate. J. Med. Chem. 2005, 48, 7457-7467.
33. Vesentini, S.; Soncini, M.; Zaupa, A.; Silvestri, V.; Fiore, G. B.; Redaelli, A. Multi-scale analysis of the toraymyxin adsorption cartridge. Part I: Molecular interaction of polymyxin B with endotoxins. Int. J. Artif. Organs 2006, 29, 239-250.
34. Vincent, J. L.; Laterre, P. F.; Cohen, J.; Burchardi, H.; Bruining, H.; Lerma, F. A.; Wittebole, X.; De Backer, D.; Brett, S.; Marzo, D.; Nakamura, H.; John, S. A pilot-controlled study of a polymyxin B-immobilized hemoperfusion cartridge in patients with severe sepsis secondary to intra-abdominal infection. Shock 2005, 23, 400-405.
35. Shoji, H. Extracorporeal endotoxin removal for the treatment of sepsis: Endotoxin adsorption cartridge (Toraymyxin). Ther. Apheresis 2003, 7, 108-114.
36. David, S. A.; Balaram, P.; Mathan, V. I. Characterization of the interaction of lipid A and lipopolysaccharide with human serum albumin: Implications for an endotoxin-carrier function for albumin. J. Endotoxin Res. 1995, 2, 99-106.
37. David, S. A. The interaction of lipid A and lipopolysaccharide with human serum albumin. In Endotoxins in health and disease; Brade, H., Opal, S. M., Vogel, S. N., Morrison, D. C., Eds.; Marcel Dekker: New York, 1999; pp 413-422.
38. Bhattacharjya, S.; David, S. A.; Mathan, V. I.; Balaram, P. Polymyxin B nonapeptide: Conformations in water and in the lipopolysaccharide-bound state determined by two-dimensional NMR and molecular dynamics. Biopolymers 1997, 41, 251-265.
39. David, S. A.; Bhattacharjya, S.; Mathan, V. I.; Balaram, P. Elucidation of the conformation of free and LPS-bound polymyxin B nonapeptide in water by 2D-NMR and restrained molecular dynamics methods and molecular modeling of polymyxin-lipid A complex. J. Endotoxin. Res. 1994, 1 (suppl), A60.
40. David, S. A.; Balaram, P.; Mathan, V. I. Interaction of basic amphiphilic polypeptide antimicrobials, gramicidin S, tyrocidin and efrapeptin, with endotoxic lipid A. Med. Microbiol. Lett. 1993, 2, 42-47.
41. David, S. A.; Mathan, V. I.; Balaram, P. Interaction of melittin with endotoxic lipid A. Biochim. Biophys. Acta 1992, 1123, 269-274.
42. David, S.A.; Awasthi, S. K.; Balaram, P. The role of polar and facial amphipathic character in determining lipopolysaccharide-binding properties in synthetic cationic peptides. J. Endotoxin Res. 2000, 6, 249-256.
43. David, S. A.; Bechtel, B.; Annaiah, C.; Mathan, V. I.; Balaram, P. Interaction of cationic amphiphilic drugs with lipid A: Implications for development of endotoxin antagonists. Biochim. Biophys. Acta 1994, 1212, 167-175.
44. David, S. A.; Mathan, V. I.; Balaram, P. Interactions of linear dicationic molecules with lipid A: Structural requisites for optimal binding affinity. J. Endotoxin Res. 1995, 2, 325-336.
45. David, S. A.; Awasthi, S. K.; Wiese, A.; Ulmer, A. J.; Lindner, B.; Brandenburg, K.; Seydel, U.; Rietschel, E. T.; Sonesson, A.; Balaram, P. Characterization of the interactions of a polycationic, amphiphilic, terminally branched oligopeptide with lipid A and lipopolysaccharide from the deep rough mutant of Salmonella minnesota. J. Endotoxin Res. 1996, 3, 369-379.
46. David, S. A.; Silverstein, R.; Amura, C. R.; Kielian, T.; Morrison, D. C. Lipopolyamines: Novel antiendotoxin compounds that reduce mortality in experimental sepsis caused by gram-negative bacteria. Antimicrob. Agents Chemother. 1999, 43, 912-919.
47. David, S. A.; Perez, L.; Infante, M. R. Sequestration of bacterial lipopolysaccharide by bis(args) gemini compounds. Bioorg. Med. Chem. Lett. 2002, 12, 357-360.
48. Burns, M. R.; Jenkins, S. A.; Wood, S. J.; Miller, K.; David, S. A. Structure-activity relationships in lipopolysaccharide neutralizers: Design, synthesis, and biological evaluation of a 540-membered amphipathic bisamide library. J. Comb. Chem. 2006, 8, 32-43.
49. Blagbrough, I. S.; Geall, A. J.; David, S. A. Lipopolyamines incorporating the tera-amine spermine bound to an alkyl chain, sequester bacterial lipopolysaccharide. Bioorg. Med. Chem. Lett. 2000, 10, 1959-1962.
50. Burns, M. R.; Wood, S. J.; Miller, K. A.; Nguyen, T.; Cromer, J. R.; David, S. A. Lysine-spermine conjugates: hydrophobic polyamine amides as potent lipopolysaccharide sequestrants. Bioorg. Med. Chem. 2005, 13, 2523-2536.
51. Miller, K. A.; Suresh Kumar, E. V. K.; Wood, S. J.; Cromer, J. R.; Datta, A.; David, S. A. Lipopolysaccharide sequestrants: Structural correlates of activity and toxicity in novel acylhomospermines. J. Med. Chem. 2005, 48, 2589-2599.
52. Burns, M. R.; Jenkins, S. A.; Vermeulen, N. M.; Balakrishna, R.; Nguyen, T. B.; Kimbrell, M. R.; David, S. A. Structural correlation between lipophilicity and lipopolysaccharide-sequestering activity in spermine-sulfonamide analogs. Bioorg. Med. Chem. Lett. 2006, 16, 6209-6212.
53. Miller, K. A.; Suresh Kumar, E. V.; Wood, S. J.; Cromer, J. R.; Datta, A.; David, S. A. Lipopolysaccharide sequestrants: Structural correlates of activity and toxicity in novel acylhomospermines. J. Med. Chem. 2005, 48, 2589-2599.
54. Blagbrough, I. S.; Geall, A. J. Practical synthesis of unsymmetrical polyamine amides. Tetrahedron Lett. 1998, 39, 439-442.
55. Wellendorph, P.; Jaroszewski, J. W.; Hansen, S. H.; Franzyk, H. A sequential high-yielding large-scale solution-method for synthesis of philanthotoxin analogues. Eur. J. Med. Chem. 2003, 38, 117-122.
56. Jasys, V. J.; Kelbaugh, P. R.; Nason, D. M.; Phillips, D.; Rosnack, K. J.; Saccomano, N. A.; Stroh, J. G. Volkmann, R. A. Isolation, structure elucidation, and synthesis of novel hydroxylamine-containing polyamines from the venom of the agelenopsis aperta spider. J. Am. Chem. Soc. 2006, 112, 6696-6704.
57. Miller, K. A.; Suresh Kumar, E. V.; Wood, S. J.; Cromer, J. R.; Datta, A.; David, S. A. Lipopolysaccharide sequestrants: Structural correlates of activity and toxicity in novel acylhomospermines. J. Med. Chem. 2005, 48, 2589-2599.
58. Fulmer, R. W. Cyanoethylation of fatty amines using acidic ion exchange catalysis. J. Org. Chem. 1962, 27, 4115-4116.
59. O'Sullivan, M. C.; Dalrymple, D. M. A one-step procedure for the selective trifluoroacetylation of primary amino groups of polyamines. Tetrahedron Lett. 2006, 36, 3451-3452.
60. Wood, S. J.; Miller, K. A.; David, S. A. Anti-endotoxin agents. 1. Development of a fluorescent probe displacement method for the rapid identification of lipopolysaccharide-binding agents. Comb. Chem. High Throughput Screening 2004, 7, 239-249.
61. Wood, S. J.; Miller, K. A.; David, S. A. Anti-endotoxin agents. 2. Pilot high-throughput screening for novel lipopolysaccharide-recognizing motifs in small molecules. Comb. Chem. High Throughput Screening 2004, 7, 733-743.
62. Wood, S. J.; Miller, K. A.; Lushington, G. H.; Burns, M. R.; David, S. A. Anti-endotoxin agents. 3. Rapid identification of high-affinity lipopolysaccharide-binding compounds in a substituted polyamine library. Comb. Chem. High Throughput Screening 2006, 9, 27-36.
63. Balakrishna, R.; Wood, S. J.; Nguyen, T. B.; Miller, K. A.; Suresh Kumar, E. V.; Datta, A.; David, S. A. Structural correlates of antibacterial and membrane-permeabilizing activities in acylpolyamines. Antimicrob. Agents Chemother. 2006, 50, 852-861.
64. Khownium, K.; Wood, S. J.; Miller, K. A.; Balakrishna, R.; Nguyen, T. B.; Kimbrell, M. R.; Georg, G. I.; David, S. A. Novel endotoxin-sequestering compounds with terephthalaldehyde-bis-guanylhydrazone scaffolds. Bioorg. Med. Chem. Lett. 2006, 16, 1305-1308.
65. Calnan, B. J.; Tidor, B.; Biancalana, S.; Hudson, D.; Frankel, A. D. Arginine-mediated RNA recognition: the arginine fork. Science 1991, 252, 1167-1171.
66. Burns, M. R.; Jenkins, S. A.; Wood, S. J.; Miller, K.; David, S. A. Structure-activity relationships in lipopolysaccharide neutralizers: Design, synthesis, and biological evaluation of a 540-membered amphipathic bisamide library. J. Comb. Chem. 2006, 8, 32-43.
67. Khownium, K.; Wood, S. J.; Miller, K. A.; Balakrishna, R.; Nguyen, T. B.; Kimbrell, M. R.; Georg, G. I.; David, S. A. Novel endotoxin-sequestering compounds with terephthalaldehyde-bis-guanylhydrazone scaffolds. Bioorg. Med. Chem. Lett. 2006, 16, 1305-1308.
68. Seiler, N.; Duranton, B.; Vincent, F.; Gosse, F.; Renault, J.; Raul, F. Inhibition of polyamine oxidase enhances the cytotoxicity of polyamine oxidase substrates. A model study with N(1)-(n-octane-sulfonyl)spermine and human colon cancer cells. Int. J. Biochem. Cell Biol. 2000, 32, 703-716.
69. Seiler, N.; Douaud, F.; Renault, J.; Delcros, J. G.; Havouis, R.; Uriac, P.; Moulinoux, J. P. Polyamine sulfonamides with NMDA antagonist properties are potent calmodulin antagonists and cytotoxic agents. Int. J. Biochem. Cell Biol. 1998, 30, 393-406.
70. Smallwood, H. S.; Shi, L.; Squier, T. C. Increases in calmodulin abundance and stabilization of activated inducible nitric oxide synthase mediate bacterial killing in RAW 264.7 macrophages. Biochemistry 2006, 45, 9717-9726.
71. Spratt, D. E.; Newman, E.; Mosher, J.; Ghosh, D. K.; Salerno, J. C.; Guillemette, J. G. Binding and activation of nitric oxide synthase isozymes by calmodulin EF hand pairs. FEBS J. 2006, 273, 1759-1771.
72. Balakrishna, R.; Wood, S. J.; Nguyen, T. B.; Miller, K. A.; Suresh Kumar, E. V.; Datta, A.; David, S. A. Structural correlates of antibacterial and membrane-permeabilizing activities in acylpolyamines. Antimicrob. Agents Chemother. 2006, 50, 852-861.
73. David, S. A. Towards a rational development of anti-endotoxin agents: Novel approaches to sequestration of bacterial endotoxins with small molecules. J. Mol. Recognit. 2001, 14, 370-387.
74. Marton, L. J.; Pegg, A. E. Polyamines as targets for therapeutic intervention. Annu. Rev. Pharmacol. Toxicol. 1995, 35, 55-91.
75. Bergeron, R. J.; Neims, A. H.; McManis, J. S.; Hawthorne, T. R.; Vinson, J. R.; Bortell, R.; Ingeno, M. J. Synthetic polyamine analogues as antineoplastics. J. Med. Chem. 1988, 31, 1183-1190.
76. Bernacki, R. J.; Bergeron, R. J.; Porter, C. W. Antitumor activity of N,N′-bis(ethyl)spermine homologues against human MALME-3 melanoma xenografts. Cancer Res. 1992, 52, 2424-2430.
77. Chang, B. K.; Bergeron, R. J.; Porter, C. W.; Vinson, J. R.; Liang, Y.; Libby, P. R. Regulatory and antiproliferative effects of N-alkylated polyamine analogues in human and hamster pancreatic adenocarcinoma cell lines. Cancer Chemother. Pharmacol. 1992, 30, 183-188.
78. Chang, B. K.; Bergeron, R. J.; Porter, C. W.; Liang, Y. Antitumor effects of N-alkylated polyamine analogues in human pancreatic adenocarcinoma models. Cancer Chemother. Pharmacol. 1992, 30, 179-182.
79. 1-acetyltransferase on polyamine pool dynamics, cell growth, and sensitivity to polyamine analogs. J. Biol. Chem. 2000, 275, 38319-38328.
80. 11-diethylnorspermine. Mol. Pharmacol. 1999, 55, 693-698.
81. 1-acetyltransferase by polyamines. FEBS Lett. 1996, 391, 89-94.
82. Libby, P. R.; Bergeron, R. J.; Porter, C. W. Structure-function correlations of polyamine analog-induced increases in spermidine/spermine acetyltransferase activity. Biochem. Pharmacol. 1989, 38, 1435-1442.
83. Cook, E. B.; Stahl, J. L.; Lowe, L.; Chen, R.; Morgan, E.; Wilson, J.; Varro, R.; Chan, A.; Graziano, F. M.; Barney, N. P. Simultaneous measurement of six cytokines in a single sample of human tears using microparticle-based flow cytometry: Allergies vs. non-allergics. J. Immunol. Methods 2001, 254, 109-116.
84. Freudenberg, M. A.; Galanos, C. Tumor necrosis factor alpha mediates lethal activity of killed Gram-negative and Gram-positive bacteria in D-galactosamine- treated mice. Infect. Immun. 1991, 59, 2110-2115.
85. Tracey, K. J.; Cerami, A. Tumor necrosis factor, other cytokines and disease. Annu. Rev. Cell Biol. 1993, 9, 317-343.